Al­ler­gan picks up op­tion for Ed­i­tas' rare eye dis­ease drug; Cure­Ge­net­ics bags $17M

→ Al­ler­gan has stepped in to pick up its de­vel­op­ment op­tion on Ed­i­tas‘ ex­per­i­men­tal ED­IT-101 for Leber con­gen­i­tal amau­ro­sis type 10. And the small­er biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER